Dr. Daniel Pollyea, MD
Claim this profileUniverstiy of Colorado Hospital
Affiliated Hospitals
Universtiy Of Colorado Hospital
University Of Colorado, Anschutz Cancer Pavilion
Clinical Trials Daniel Pollyea, MD is currently running
Venetoclax, Azacitidine, and Cusatuzumab
for Acute Myeloid Leukemia
The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine?
Recruiting
1 award
Phase 2
1 criteria
CC-486 + Venetoclax
for Acute Myeloid Leukemia
This is an open label, dose escalation Phase I single institution pilot study for relapsed and refractory AML patients using CC-486 (oral azacitidine) with venetoclax. At the completion of dose escalation and after establishment of the MTD or recommended dose of CC-486 with venetoclax, an expansion phase will commence, using venetoclax with the MTD of CC-486 in relapsed/refractory patients.
Recruiting
3 awards
Phase 1
16 criteria
More about Daniel Pollyea, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Daniel Pollyea, MD has experience with
- Azacitidine
- Venetoclax
- Omacetaxine
- KPT-9274
- CC-486
- IO-202
Breakdown of trials Daniel Pollyea, MD has run
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Myelodysplastic Syndrome
Monocytic Leukemia
Chronic Myelomonocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Pollyea, MD specialize in?
Daniel Pollyea, MD focuses on Acute Myeloid Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved treating patients, or patients who are undergoing treatment.
Is Daniel Pollyea, MD currently recruiting for clinical trials?
Yes, Daniel Pollyea, MD is currently recruiting for 2 clinical trials in Aurora Colorado. If you're interested in participating, you should apply.
Are there any treatments that Daniel Pollyea, MD has studied deeply?
Yes, Daniel Pollyea, MD has studied treatments such as Azacitidine, Venetoclax, Omacetaxine.
What is the best way to schedule an appointment with Daniel Pollyea, MD?
Apply for one of the trials that Daniel Pollyea, MD is conducting.
What is the office address of Daniel Pollyea, MD?
The office of Daniel Pollyea, MD is located at: Universtiy of Colorado Hospital, Aurora, Colorado 80045 United States. This is the address for their practice at the Universtiy of Colorado Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.